Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].
about
Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lungCurrent status of mucins in the diagnosis and therapy of cancer.ProtEx technology for the generation of novel therapeutic cancer vaccinesMUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1.Recent advances in the development of breast cancer vaccines.Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Dendritic cell immunotherapy: clinical outcomesMucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.MUC1-Targeted Cancer Cell Photothermal Ablation Using Bioinspired Gold Nanorods.Presentation Modality of Glycoconjugates Modulates Dendritic Cell Phenotype.Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells.Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1Natural and Induced Humoral Responses to MUC1.Strategies used for MUC1 immunotherapy: human clinical studies.Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors.Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.Progress in the development of a therapeutic vaccine for breast cancer.MUC1 and metastatic cancer: expression, function and therapeutic targeting.MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.MUC1 immunotherapy.MUC1 immunotherapy is here to stay.MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.C-type Lectin Receptors for Tumor Eradication: Future Directions.Emerging immunotherapy strategies in breast cancer.Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization.Update on Mucin-1 immunotherapy in cancer: a clinical perspective.Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen.A Review of Water-Resistant Hemicellulose-Based Materials: Processing and Applications.Multiple Sclerosis: Immunopathology and Treatment Update.Cancer immunotherapy.Mannan-mediated gene delivery for cancer immunotherapy.MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes.Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1.Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.Progress in Vaccine Therapies for Breast Cancer.Mannosylated T/Tn with Freund's adjuvant induces cellular immunity.
P2860
Q30373884-2FC125BC-10B5-4730-8665-F37A687984E5Q33757326-8A956E10-03F4-4E9D-A216-BB2B9D434277Q34048819-6040CDA2-C913-49CA-A35F-6E909CA02196Q34206162-52413E36-2DD5-411A-A194-31CC5B71252CQ34269196-6E602A71-384D-42B8-AC0D-67CE60632927Q34379303-C1380E95-7DD3-445F-AEE0-F4E7BEE7B246Q34494018-157D42A1-67EE-40AF-AD53-C8A3A4089A5BQ34511606-38CDADF9-4BD9-4CD5-B972-9BE890E9D840Q35551987-06B3D693-B6A4-4A39-9C4D-0012CF74AAFBQ35683902-CBAFE15C-0355-4B17-A0A4-2E15D15BBA71Q35801322-38006F5A-2A41-4804-A177-C5F2235B97BEQ36510283-232E5661-5C80-4D18-BEC0-16CE5E21EACDQ36915898-03059878-1535-4ACA-975C-DA69949FE251Q37137385-68184A53-4AF1-4944-A204-C1809E31DB4DQ37259597-2576704F-DC12-4E12-A4B8-999972B6F3CAQ37259611-ECABC3E2-ED8B-4B1E-8AE4-6CE5255453AEQ37338140-CF1877A2-2F89-4221-AE55-0DBC6A84B185Q37354177-73617B59-8652-4265-8AD5-E27BD2876A47Q37355578-D56D0934-8680-498B-B49C-A802384ECDDEQ37636939-96C762A6-A5D3-4818-B5B5-D7F19B9FA631Q37737313-44702E5E-9FD6-408A-AC21-82E37326E7EAQ37773241-1D893A4E-127D-406F-A8CA-0661BE4D4ABCQ38045428-B3FA0EA1-D65A-46E6-A78C-9B9EEAC390B6Q38091088-969CA31C-BD54-4EA8-AC11-37A02CE8E83EQ38161368-4D5B53A3-D9E6-4F94-820F-D5707C9E0220Q38184650-A4C6CD53-EFCB-4C2C-BA4E-090B64CC2D4BQ38336731-12B53894-707D-4BDD-8B32-92CB2712F076Q38603410-1C6DE75F-50FC-4EA1-AED6-8C7113784AB7Q38966611-2D7C14D1-24EC-4407-8262-83E3E021BD3CQ39060582-4DD0E4CD-DB81-4CF1-8892-764ECB9D8CC3Q39420793-8A0D4A6F-78E2-45DC-B381-78DFC0A2B2D6Q39958332-3A2CD368-DDE0-49F5-9780-24A40A10978DQ40165469-8FD7940F-5B93-447F-9FDA-7B62D78E9308Q40197046-284E0CDA-EA16-4E8D-83F8-8BFA3C971166Q41201112-CF6B7CDB-609C-4BFA-9B87-A73044D6C56BQ42160992-ECB8537F-5607-482F-9440-192CE15DE4F9Q46437199-9729AF16-0D61-49AF-85BD-9FA294535063Q47233994-4007AB5E-FD12-44B0-891F-64062E44106CQ48556381-0D3F2C14-EE46-41BA-B792-DF001BFACC6FQ48566108-DC7C1EED-E5C6-4BC3-9277-BF44F151BAF2
P2860
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].
@ast
Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].
@en
type
label
Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].
@ast
Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].
@en
prefLabel
Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].
@ast
Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].
@en
P2093
P2860
P356
P1476
Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].
@en
P2093
Anastasios Tsibanis
Annivas Tsikkinis
Bruce E Loveland
Dodie S Pouniotis
Geoffrey A Pietersz
Heleni Drakaki
Ian F McKenzie
Magdalena Plebanski
Michael N Alexis
Sara J Piddlesden
P2860
P2888
P356
10.1186/BCR1505
P577
2006-06-15T00:00:00Z
P5875
P6179
1002067821